Haleon plc, a leading company in the consumer health sector, announced today that as of Monday, the total number of issued shares with voting rights stands at 9,133,887,197 ordinary shares, each with a nominal value of £0.01. The company confirmed that no ordinary shares are currently held in Treasury.
This figure is significant for shareholders and other parties with notification obligations, as it serves as the denominator for calculations related to the disclosure of interest changes in the company, as per the Financial Conduct Authority's Disclosure and Transparency Rules.
The company, known for its portfolio of products across major categories such as Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements, emphasizes its commitment to delivering better everyday health with humanity. Haleon's trusted brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, which are based on scientific research and consumer insights.
Haleon is listed on both the London Stock Exchange (LSE) and the New York Stock Exchange (NYSE) under the ticker symbol HLN. For further information about the company and its brands, Haleon invites visitors to explore its website.
In other recent news, Haleon plc has finalized the divestment of its nicotine replacement therapy (NRT) business outside the United States to Dr. Reddy's Laboratories SA. The transaction, initially disclosed in June 2024, involves a total consideration of up to £500 million. This strategic move aligns with Haleon's focus on core consumer health categories.
In addition to this, Haleon has decided to acquire an additional 33% equity stake in its Chinese joint venture, Tianjin TSKF Pharmaceutical Co. Ltd. This acquisition is expected to increase Haleon's ownership to 88%, thus strengthening its strategic position in the Chinese market. The company also recently launched a dual-tranche bond offering as part of its Euro Medium Term Note program.
Recent analyst notes reveal that Morgan Stanley and BofA Securities have upgraded Haleon's stock price target, maintaining a positive rating. However, Goldman Sachs has downgraded Haleon's stock from "Buy" to "Neutral," while Berenberg initiated coverage with a "Buy" rating.
Haleon has also made significant strides in product development, launching Eroxon®, the first FDA-cleared over-the-counter gel for the treatment of erectile dysfunction in the United States. Corporate structure changes include the welcoming of two new board members, Alan Stewart and Nancy Avila.
InvestingPro Insights
Haleon's recent announcement about its share count aligns with several key financial metrics and insights from InvestingPro. The company's market capitalization stands at $48.39 billion, reflecting its significant presence in the consumer health sector.
InvestingPro data reveals that Haleon boasts impressive gross profit margins, with a gross profit margin of 62.54% for the last twelve months as of Q2 2024. This underscores the company's ability to maintain profitability across its diverse portfolio of trusted brands.
Additionally, Haleon's stock has shown strong performance recently, with a 29.88% price total return over the past three months. This positive momentum is further supported by the fact that the stock is trading near its 52-week high, at 97.59% of that peak.
InvestingPro Tips highlight that Haleon operates with a moderate level of debt and is expected to be profitable this year, according to analyst predictions. These factors, combined with the company's strong brand portfolio and market position, suggest a stable outlook for the company.
For investors seeking more comprehensive analysis, InvestingPro offers 8 additional tips for Haleon, providing deeper insights into the company's financial health and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.